These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29042634)

  • 1. A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease.
    Skillbäck T; Mattsson N; Hansson K; Mirgorodskaya E; Dahlén R; van der Flier W; Scheltens P; Duits F; Hansson O; Teunissen C; Blennow K; Zetterberg H; Gobom J
    Sci Rep; 2017 Oct; 7(1):13333. PubMed ID: 29042634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
    Hölttä M; Minthon L; Hansson O; Holmén-Larsson J; Pike I; Ward M; Kuhn K; Rüetschi U; Zetterberg H; Blennow K; Gobom J
    J Proteome Res; 2015 Feb; 14(2):654-63. PubMed ID: 25490617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications.
    Deolankar SC; Patil AH; Koyangana SG; Subbannayya Y; Prasad TSK; Modi PK
    OMICS; 2019 Jul; 23(7):350-361. PubMed ID: 31225774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid.
    Vafadar-Isfahani B; Ball G; Coveney C; Lemetre C; Boocock D; Minthon L; Hansson O; Miles AK; Janciauskiene SM; Warden D; Smith AD; Wilcock G; Kalsheker N; Rees R; Matharoo-Ball B; Morgan K
    J Alzheimers Dis; 2012; 28(3):625-36. PubMed ID: 22045497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease.
    Öhrfelt A; Brinkmalm A; Dumurgier J; Brinkmalm G; Hansson O; Zetterberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
    Alzheimers Res Ther; 2016 Oct; 8(1):41. PubMed ID: 27716408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study.
    Russell CL; Heslegrave A; Mitra V; Zetterberg H; Pocock JM; Ward MA; Pike I
    Rapid Commun Mass Spectrom; 2017 Jan; 31(2):153-159. PubMed ID: 27813239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
    Robinson RA; Amin B; Guest PC
    Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease.
    Kang S; Jeong H; Baek JH; Lee SJ; Han SH; Cho HJ; Kim H; Hong HS; Kim YH; Yi EC; Seo SW; Na DL; Hwang D; Mook-Jung I
    J Alzheimers Dis; 2016 Jul; 53(4):1563-76. PubMed ID: 27392853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer's disease biomarkers.
    van Zalm PW; Ahmed S; Fatou B; Schreiber R; Barnaby O; Boxer A; Zetterberg H; Steen JA; Steen H
    Cell Rep Med; 2023 Apr; 4(4):101005. PubMed ID: 37075703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Relevance of Neuroproteomics in Alzheimer's Disease.
    Lista S; Zetterberg H; O'Bryant SE; Blennow K; Hampel H
    Methods Mol Biol; 2017; 1598():101-115. PubMed ID: 28508359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer's Disease.
    Shah DJ; Rohlfing F; Anand S; Johnson WE; Alvarez MT; Cobell J; King J; Young SA; Kauwe JS; Graves SW
    J Alzheimers Dis; 2016; 49(2):317-27. PubMed ID: 26484917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposing the Brain Proteomic Signatures of Alzheimer's Disease in Diverse Racial Groups: Leveraging Multiple Data Sets and Machine Learning.
    Desaire H; Stepler KE; Robinson RAS
    J Proteome Res; 2022 Apr; 21(4):1095-1104. PubMed ID: 35276041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration.
    Oeckl P; Steinacker P; von Arnim CA; Straub S; Nagl M; Feneberg E; Weishaupt JH; Ludolph AC; Otto M
    J Proteome Res; 2014 Nov; 13(11):4518-25. PubMed ID: 25091646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum biomarkers for Alzheimer's disease: proteomic discovery.
    German DC; Gurnani P; Nandi A; Garner HR; Fisher W; Diaz-Arrastia R; O'Suilleabhain P; Rosenblatt KP
    Biomed Pharmacother; 2007 Aug; 61(7):383-9. PubMed ID: 17614251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies.
    Zelaya MV; Pérez-Valderrama E; de Morentin XM; Tuñon T; Ferrer I; Luquin MR; Fernandez-Irigoyen J; Santamaría E
    Oncotarget; 2015 Nov; 6(37):39437-56. PubMed ID: 26517091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.